These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1114 related articles for article (PubMed ID: 34325252)

  • 1. Characteristics of discharge prescriptions for patients with schizophrenia or major depressive disorder: Real-world evidence from the Effectiveness of Guidelines for Dissemination and Education (EGUIDE) psychiatric treatment project.
    Hashimoto N; Yasui-Furukori N; Hasegawa N; Ishikawa S; Numata S; Hori H; Iida H; Ichihashi K; Furihata R; Murata A; Tsuboi T; Takeshima M; Kyou Y; Komatsu H; Kubota C; Ochi S; Takaesu Y; Usami M; Nagasawa T; Hishimoto A; Miura K; Matsumoto J; Ohi K; Yamada H; Inada K; Watanabe K; Shimoda K; Hashimoto R
    Asian J Psychiatr; 2021 Sep; 63():102744. PubMed ID: 34325252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prescription patterns in patients with schizophrenia in Japan: First-quality indicator data from the survey of "Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE)" project.
    Ichihashi K; Hori H; Hasegawa N; Yasuda Y; Yamamoto T; Tsuboi T; Iwamoto K; Kishimoto T; Horai T; Yamada H; Sugiyama N; Nakamura T; Tsujino N; Nemoto K; Oishi S; Usami M; Katsumoto E; Yamamori H; Tomita H; Suwa T; Furihata R; Inagaki T; Fujita J; Onitsuka T; Miura K; Matsumoto J; Ohi K; Matsui Y; Takaesu Y; Hashimoto N; Iga J; Ogasawara K; Yamada H; Watanabe K; Inada K; Hashimoto R
    Neuropsychopharmacol Rep; 2020 Sep; 40(3):281-286. PubMed ID: 32602667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Change of prescription for patients with schizophrenia or major depressive disorder during admission: real-world prescribing surveys from the effectiveness of guidelines for dissemination and education psychiatric treatment project.
    Hashimoto N; Yasui-Furukori N; Hasegawa N; Ishikawa S; Hori H; Iida H; Ichihashi K; Miura K; Matsumoto J; Numata S; Kodaka F; Furihata R; Ohi K; Ogasawara K; Iga JI; Muraoka H; Komatsu H; Takeshima M; Atake K; Kido M; Nakamura T; Kishimoto T; Hishimoto A; Onitsuka T; Okada T; Ochi S; Nagasawa T; Makinodan M; Yamada H; Tsuboi T; Yamada H; Inada K; Watanabe K; Hashimoto R
    BMC Psychiatry; 2023 Jun; 23(1):473. PubMed ID: 37380997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypnotic medication use among inpatients with schizophrenia and major depressive disorder: results of a nationwide study.
    Furihata R; Otsuki R; Hasegawa N; Tsuboi T; Numata S; Yasui-Furukori N; Kashiwagi H; Hori H; Ochi S; Muraoka H; Onitsuka T; Komatsu H; Takeshima M; Hishimoto A; Nagasawa T; Takaesu Y; Nakamura T; Asami T; Miura K; Matsumoto J; Ohi K; Yasuda Y; Iida H; Ogasawara K; Hashimoto N; Ichihashi K; Yamada H; Watanabe K; Inada K; Hashimoto R
    Sleep Med; 2022 Jan; 89():23-30. PubMed ID: 34875519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnoses associated with use of atypical antipsychotics in a commercial health plan: a claims database analysis.
    Citrome L; Kalsekar I; Guo Z; Laubmeier K; Hebden T
    Clin Ther; 2013 Dec; 35(12):1867-75. PubMed ID: 24119767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The characteristics of patients receiving psychotropic pro re nata medication at discharge for the treatment of schizophrenia and major depressive disorder: A nationwide survey from the EGUIDE project.
    Ichihashi K; Kyou Y; Hasegawa N; Yasui-Furukori N; Shimizu Y; Hori H; Hashimoto N; Ide K; Imamura Y; Yamada H; Ochi S; Iga JI; Takaesu Y; Ohi K; Tsuboi T; Iida H; Yamagata H; Hishimoto A; Horai T; Usami M; Makinodan M; Nagasawa T; Komatsu H; Kido M; Muraoka H; Atake K; Takeshima M; Kubota C; Inagaki T; Tamai S; Kishimoto T; Furihata R; Matsumoto J; Miura K; Inada K; Watanabe K; Kasai K; Hashimoto R
    Asian J Psychiatr; 2022 Mar; 69():103007. PubMed ID: 35051727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of education regarding treatment guidelines for schizophrenia and major depressive disorders on psychiatrists' hypnotic medication prescribing behavior: a multicenter study.
    Nakamura T; Furihata R; Hasegawa N; Kodaka F; Muraoka H; Ichihashi K; Ochi S; Numata S; Tsuboi T; Makinodan M; Iida H; Onitsuka T; Kashiwagi H; Takeshima M; Hashimoto N; Nagasawa T; Usami M; Yamagata H; Takaesu Y; Miura K; Matsumoto J; Ohi K; Yamada H; Hori H; Inada K; Watanabe K; Hashimoto R; Yasui-Furukori N
    BMC Psychiatry; 2024 May; 24(1):399. PubMed ID: 38807065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of education regarding treatment guidelines for schizophrenia and depression on the treatment behavior of psychiatrists: A multicenter study.
    Hasegawa N; Yasuda Y; Yasui-Furukori N; Yamada H; Hori H; Ichihashi K; Takaesu Y; Iida H; Muraoka H; Kodaka F; Iga JI; Hashimoto N; Ogasawara K; Ohi K; Fukumoto K; Numata S; Tsuboi T; Usami M; Hishimoto A; Furihata R; Kishimoto T; Nakamura T; Katsumoto E; Ochi S; Nagasawa T; Atake K; Kubota C; Komatsu H; Yamagata H; Ide K; Takeshima M; Kido M; Kikuchi S; Okada T; Matsumoto J; Miura K; Shimazu T; Inada K; Watanabe K; Hashimoto R
    Psychiatry Clin Neurosci; 2023 Oct; 77(10):559-568. PubMed ID: 37684711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The characteristics of discharge prescriptions including pro re nata psychotropic medications for patients with schizophrenia and major depressive disorder from the survey of the "Effectiveness of guidelines for dissemination and education in psychiatric treatment (EGUIDE)" project.
    Kyou Y; Yasui-Furukori N; Hasegawa N; Ide K; Ichihashi K; Hashimoto N; Hori H; Shimizu Y; Imamura Y; Muraoka H; Iida H; Ohi K; Yasuda Y; Ogasawara K; Numata S; Iga JI; Tsuboi T; Ochi S; Kodaka F; Furihata R; Onitsuka T; Makinodan M; Komatsu H; Takeshima M; Kubota C; Hishimoto A; Atake K; Yamagata H; Kido M; Nagasawa T; Usami M; Kishimoto T; Kikuchi S; Matsumoto J; Miura K; Yamada H; Watanabe K; Inada K; Hahimoto R
    Ann Gen Psychiatry; 2022 Dec; 21(1):52. PubMed ID: 36567327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in Prescription of Psychotropic Drugs After Introduction of Polypharmacy Reduction Policy in Japan Based on a Large-Scale Claims Database.
    Hirano Y; Ii Y
    Clin Drug Investig; 2019 Nov; 39(11):1077-1092. PubMed ID: 31399894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of antipsychotic prescription to patients with schizophrenia in Korea: results from the health insurance review & assessment service-national patient sample.
    Park SC; Lee MS; Kang SG; Lee SH
    J Korean Med Sci; 2014 May; 29(5):719-28. PubMed ID: 24851031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Non-Interventional Naturalistic Study of the Prescription Patterns of Antipsychotics in Patients with Schizophrenia from the Spanish Province of Tarragona.
    Gaviria AM; Franco JG; Aguado V; Rico G; Labad J; de Pablo J; Vilella E
    PLoS One; 2015; 10(10):e0139403. PubMed ID: 26427051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. National trends in psychotropic medication polypharmacy in office-based psychiatry.
    Mojtabai R; Olfson M
    Arch Gen Psychiatry; 2010 Jan; 67(1):26-36. PubMed ID: 20048220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of medical fee revisions for psychotropic polypharmacy in patients with mood disorders in Japan: An interrupted time-series analysis using a nationwide inpatient database.
    Yamazaki R; Ohbe H; Matsuda Y; Kito S; Shigeta M; Morita K; Matsui H; Fushimi K; Yasunaga H
    Asian J Psychiatr; 2023 Jun; 84():103581. PubMed ID: 37086613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in antipsychotic prescriptions for Japanese outpatients during 2006-2012: a descriptive epidemiological study.
    Kochi K; Sato I; Nishiyama C; Tanaka-Mizuno S; Doi Y; Arai M; Fujii Y; Matsunaga T; Ogawa Y; Furukawa TA; Kawakami K
    Pharmacoepidemiol Drug Saf; 2017 Jun; 26(6):642-656. PubMed ID: 28266090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study on the prescribing patterns of antipsychotic medication in a rural England Community Mental Health Team.
    Seshadri M; Elsemary A; Thalitaya MD; Chikodzore L; Nagalingam P
    Psychiatr Danub; 2017 Sep; 29(Suppl 3):524-529. PubMed ID: 28953820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prescribing patterns of antidepressants, antipsychotics and mood stabilizers in bipolar patients misdiagnosed with major depressive disorder in China.
    Xiang YT; Hu C; Wang G; Zheng QW; Fang YR; Ungvari GS; Kilbourne AM; Lai KY; Si TM; Chen DF; Lu Z; Yang HC; Hu J; Chen ZY; Huang Y; Sun J; Wang XP; Li HC; Zhang JB; Chiu HF
    Hum Psychopharmacol; 2012 Nov; 27(6):626-31. PubMed ID: 23027671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polypharmacy and psychotropic drug loading in patients with schizophrenia in Asian countries: Fourth survey of Research on Asian Prescription Patterns on antipsychotics.
    Yang SY; Chen LY; Najoan E; Kallivayalil RA; Viboonma K; Jamaluddin R; Javed A; Hoa DTQ; Iida H; Sim K; Swe T; He YL; Park Y; Ahmed HU; De Alwis A; Chiu HF; Sartorius N; Tan CH; Chong MY; Shinfuku N; Lin SK
    Psychiatry Clin Neurosci; 2018 Aug; 72(8):572-579. PubMed ID: 29761577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How psychotropic polypharmacy in schizophrenia begins: a longitudinal perspective.
    Shinfuku M; Uchida H; Tsutsumi C; Suzuki T; Watanabe K; Kimura Y; Tsutsumi Y; Ishii K; Imasaka Y; Mimura M; Kapur S
    Pharmacopsychiatry; 2012 Jun; 45(4):133-7. PubMed ID: 22174025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.